Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics

Alex Chehrazi-Raffle, MD from City of Hope outlines recent advances in non-metastatic prostate cancer treatment, notably the use of androgen receptor pathway inhibitors (ARPIs) for patients with a PSADT of less than 10 months, have significantly delayed the progression to metastatic disease, with the DEAR study highlighting darolutamide's effectiveness in reducing discontinuations or metastasis progression, marking a pivotal shift in early intervention strategies..